Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raynier Devillier

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|April 14, 2016
Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patientsRaynier Devillier, Angela Granata, Sabine Fürst, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2023
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?Mourad Hamimed, Raynier Devillier, Pierre-Jean Weiller, et al.
Frontiers in Medicine|April 17, 2023
Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysisWen-Hui Gao, Jia-Yan Zhu, Li-Ning Wang, et al.
Hematological Oncology|December 5, 2013
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphomaSylvain Garciaz, Diane Coso, Frederic Peyrade, et al.
Bone Marrow Transplantation|August 8, 2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-CalmettesLing Wang, Raynier Devillier, Ming Wan, et al.
American Journal of Hematology|January 31, 2017
Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimenAude Collignon, Boris Calmels, Samia Harbi, et al.
BMC Cancer|August 7, 2014
Constitutive AKT activation in follicular lymphomaOuardia I Yahiaoui, Jacques A Nunès, Céline Castanier, et al.
American Journal of Hematology|September 16, 2014
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patientsRaynier Devillier, Véronique Gelsi-Boyer, Anne Murati, et al.
Cancers|June 2, 2021
Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling DonorRaynier Devillier, Boris Calmels, Sophie Guia, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|April 14, 2016
Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patientsRaynier Devillier, Angela Granata, Sabine Fürst, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2023
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?Mourad Hamimed, Raynier Devillier, Pierre-Jean Weiller, et al.
Frontiers in Medicine|April 17, 2023
Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysisWen-Hui Gao, Jia-Yan Zhu, Li-Ning Wang, et al.
Hematological Oncology|December 5, 2013
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphomaSylvain Garciaz, Diane Coso, Frederic Peyrade, et al.
Bone Marrow Transplantation|August 8, 2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-CalmettesLing Wang, Raynier Devillier, Ming Wan, et al.
American Journal of Hematology|January 31, 2017
Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimenAude Collignon, Boris Calmels, Samia Harbi, et al.
BMC Cancer|August 7, 2014
Constitutive AKT activation in follicular lymphomaOuardia I Yahiaoui, Jacques A Nunès, Céline Castanier, et al.
American Journal of Hematology|September 16, 2014
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patientsRaynier Devillier, Véronique Gelsi-Boyer, Anne Murati, et al.
Cancers|June 2, 2021
Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling DonorRaynier Devillier, Boris Calmels, Sophie Guia, et al.
Pageof 12